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a  b  s  t  r  a  c  t
IgE  antibody-mediated  allergies  affect more  than  25%  of the  population  worldwide.  To  investigate  thera-
peutic and  preventive  effects  of  passive  immunization  with  allergen-speciﬁc  IgG  antibodies  on allergy  in
mouse models  we  used  clinically  relevant  pollen  allergens.  In a treatment  model,  mice  were  sensitized
to  the  major  birch  pollen  allergen  Bet  v 1 and  to the  major  grass  pollen  allergens,  Phl  p  1 and  Phl  p  5  and
then  received  passive  immunization  with  rabbit  IgG  antibodies  speciﬁc  for  the  sensitizing  or  an  unre-
lated  allergen.  In  a  prevention  model,  mice  obtained  passive  immunization  with  allergen-speciﬁc  rabbit
IgG  before  sensitization.  Kinetics  of  the  levels  of  administered  IgG  antibodies,  effects  of administered
allergen-speciﬁc  IgG  on  allergen-speciﬁc  IgE  reactivity,  the  development  of  IgE  and  IgG  responses  and  on
immediate  allergic  reactions  were  studied  by  ELISA,  rat  basophil  leukaemia  degranulation  assays  and  skin
testing,  respectively.  Treated  mice  showed  an approximately  80%  reduction  of  allergen-speciﬁc  IgE  bind-ouse
assive immunization
ing  and  basophil  degranulation  which  was  associated  with  the  levels  of  administered  allergen-speciﬁc  IgG
antibodies.  Preventive  administration  of  allergen-speciﬁc  IgG  antibodies  suppressed  the  development  of
allergen-speciﬁc  IgE  and  IgG1 antibody  responses  as  well  as  allergen-induced  basophil  degranulation
and  skin  reactivity.  Our  results  show  that  passive  immunization  with  allergen-speciﬁc  IgG antibodies
is  effective  for  treatment  and  prevention  of  allergy  to  clinically  important  pollen  allergens  in  a mouse
model  and thus  may  pave  the  road  for  the  clinical  application  of allergen-speciﬁc  antibodies  in humans.ntroduction
IgE-mediated allergy affects more than 25% of the popula-
ion worldwide and shows a continuously increasing prevalence
Floistrup et al. 2006). Allergen-speciﬁc immunotherapy (SIT) is
urrently the only antigen-speciﬁc, disease-modifying treatment
f allergy and has long-lasting effects (Shamji and Durham 2011).
ince the ﬁrst reports indicated that SIT induces allergen-speciﬁc
gG antibodies which block IgE-mediated inﬂammation (Cooke
t al. 1935; Loveless 1940), it has been shown that SIT-induced
llergen-speciﬁc IgG also reduces T cell reactivity and boosts of IgE
roduction (Larche et al. 2006). Passive immunization of patients
ith allergen-speciﬁc IgG antibodies has been successfully used
o far only in combination with active SIT mainly to reduce the
Abbreviations: i.n., intranasal; SIT, allergen-speciﬁc immunotherapy.
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E-mail address: Sabine.ﬂicker@meduniwien.ac.at (S. Flicker).
171-2985 © 2012 Elsevier GmbH. 
ttp://dx.doi.org/10.1016/j.imbio.2012.10.008
Open access under CC BY-NC-ND license.© 2012 Elsevier GmbH. 
sensitivity of patients but not yet as sole treatment procedure
(Bernstein et al. 1979; Bousquet et al. 1987; Muller et al. 1986). It
has been also reported that SIT-induced allergen-speciﬁc IgG anti-
bodies cross the placenta (Flicker et al. 2009) and may  protect the
offspring from sensitization (Glovsky et al. 1991). Furthermore, it
has been demonstrated that elevated cord blood levels of allergen-
speciﬁc IgG are associated with less allergy development in children
(Jenmalm and Bjorksten 2000).
Experimental studies performed in mice and rats with model
antigens such as ovalbumin suggested that prenatal active immu-
nization induces allergen-speciﬁc IgG antibodies which protect
against allergen-induced sensitization and allergic inﬂammation in
the off-spring (Fusaro et al. 2007; Jarrett and Hall 1983; Polte and
Hansen 2008; Polte et al. 2008; Uthoff et al. 2003). There are also
experimental animal studies using ovalbumin or goat-anti IgD as
immunogens demonstrating that passive administration of speciﬁc
IgG antibodies may  be effective in suppressing allergic sensitiza-
tion, allergic inﬂammation and even anaphylactic shock (Moerch
et al. 2006; Sehra et al. 2003; Strait et al. 2006; Uthoff et al. 2003).
Open access under CC BY-NC-ND license.However, so far no studies have been performed with allergens
which are relevant for allergy in humans. Here we used clinically
important grass pollen allergens (i.e., Phl p 1, Phl p 5) (Laffer et al.
1994; Vrtala et al. 1993; Westritschnig et al. 2008), the major
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Fig. 1. Scheme of treatment by passive immunization with allergen-speciﬁc IgG antibodies. Groups of 10 mice were sensitized three times (days 1, 14 and 31) with aluminium
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irch pollen allergen Bet v 1 (Breiteneder et al. 1989; Niederberger
t al. 1998a,b; Pauli et al. 2008) and corresponding allergen-speciﬁc
gG antibodies to investigate whether passive immunization with
llergen-speciﬁc IgG antibodies can suppress IgE-mediated allergic
eactions in a mouse model for treatment. Furthermore, we studied
n a preventive mouse model if passive immunization can suppress
llergic sensitization.
aterials and methods
llergens, animals, rabbit immune sera
Puriﬁed recombinant allergens (rBet v 1, rPhl p 1, rPhl p 5)
ere obtained from BIOMAY (Vienna, Austria). Female 6–8 week-
ld BALB/c mice were purchased from Charles River (Sulzfeld,
ermany) and kept in the animal care unit of the Department
f Pathophysiology and Allergy Research, Medical University of
ienna according to the local guidelines for animal care. All animal
xperiments were approved by the Animal Ethics Committee of
he Medical University of Vienna and the Austrian Federal Ministry
f Science and Research (66009/186-II/10b/2008). Pollen allergen-
peciﬁc rabbit IgG antibodies were obtained by immunization of
abbits with puriﬁed recombinant allergens (rBet v 1, rPhl p 1, rPhl
 5) using complete and incomplete Freund’ s adjuvant (CFA, IFA),
espectively (Charles River, Kislegg, Germany).
days
Sensitizatio n to
rPhl p 5
in Al (OH)3 (n=10 )
- 1
0 1 2
Sera after sensit izatPre-immun eserum
8 14
Administ rat ion  of
Phl p 5- (pr ophylaxis)  or Phl  p 2-spec ific 
IgG antibod ies (control)  i.p.
Administ r
Phl p 5- (pr ophylaxis) 
IgG antibod ies
ig. 2. Scheme for prophylactic administration of allergen-speciﬁc IgG antibodies. Mice
roup)  and were then sensitized to Phl p 5. Bleeding, administration of antibodies and intgen-speciﬁc IgG or IgG speciﬁc for an unrelated allergen. Sera were obtained at the
Sensitization and passive antibody treatment of mice
For the therapy model, mice were sensitized by three sub-
cutaneous (s.c.) immunizations (days 1, 14 and 31) with each
of the puriﬁed recombinant allergens (5 g/mouse) adsorbed
to aluminium hydroxide (Al(OH)3) (Alu-Gel-S; Serva, Ingelheim,
Germany) (Fig. 1). Groups of ten mice each were sensitized to
rBet v 1, rPhl p 1 or rPhl p 5. Blood samples were taken from
the tail veins before sensitization, at day 34 and at days 39, 41,
45, 52 and 59 (Fig. 1). Allergic sensitization was  conﬁrmed by the
measurement of allergen-speciﬁc IgE antibodies at day 34. Mice
were then randomized into groups of 5 mice so that mice of each
group had comparable allergen-speciﬁc IgE levels. Mice in the treat-
ment groups received one intraperitoneal (i.p.) injection of 0.5 ml
allergen-speciﬁc rabbit IgG whereas mice from the control groups
received one i.p. injection of rabbit IgG speciﬁc for an unrelated
allergen (Fig. 1).
For the preventive model, groups of mice (n = 5) received either
i.p. 0.5 ml  Phl p 5-speciﬁc rabbit IgG antibodies (prophylaxis group)
or 0.5 ml  rabbit IgG antibodies speciﬁc for an unrelated allergen, Phl
p 2 (control group) on day 0 and, on day 14 (Fig. 2). On day 1 mice
of both groups were simultaneously sensitized s.c. with 5 g rPhl
p 5 and 5 g rBet v 1 adsorbed to aluminium hydroxide (Al(OH)3).
Blood was  collected from the tail veins before sensitization as well
as on days 2, 8 and 20 (Fig. 2).
ion
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Fig. 3. Changes of speciﬁc IgE binding to allergens ((A) Bet v 1; (B and C) Phl p 1; (D) Phl p 5) in treated mouse groups. The percentages inhibition of allergen-speciﬁc IgE
binding  are shown for the individual mice at different points of time (x-axes: 24 h, 72 h, 1 week, 2 week, 3 week) after treatment with allergen-speciﬁc IgG antibodies (left
p es). M
a over t
g
M
a
E
r
4
M
d
I
p
I
a
m
i
w
l
d
i
P
s
b
(
b
canels)  or with IgG antibodies speciﬁc for an unrelated allergen (right panels) (y-ax
llergen-speciﬁc IgE are shown as box plots with indicated median values (y-axis) 
roup  shown in (B).
easurement of total IgE levels, allergen-speciﬁc IgE and IgG1
ntibodies as well as of allergen-speciﬁc rabbit IgG in mouse sera
Total IgE antibody levels were determined in mice using an IgE
LISA Set (Becton Dickinson, New Jersey, US). Optical densities cor-
esponding to bound IgE antibodies (OD at 405 nm, reference OD at
90 nm)  were determined with an ELISA reader (Spectramax PLUS,
olecular Devices, Sunnyvale, CA). Results are means of duplicate
eterminations with variations of less than 10%. To determine the
gE concentrations, mean OD values of the tested sera were com-
ared to the mean OD values of the standard curve and calculated
gE titres were multiplied by the dilution factor of the tested sera
nd expressed in ng/ml.
Allergen-speciﬁc mouse IgE and IgG1 antibodies were deter-
ined by ELISA (Linhart et al. 2007). Optical densities correspond-
ng to bound antibodies (OD at 405 nm,  reference OD at 490 nm)
ere determined with an ELISA reader (Spectramax PLUS, Molecu-
ar Devices, Sunnyvale, CA). Results represented means of duplicate
eterminations with variations of less than 10%. The percentage
nhibition of IgE binding by rabbit IgG was calculated as follows:
ercentage inhibition = 100 − ODserum after treatment × 100/OD
erum before treatment.
Allergen-speciﬁc rabbit IgG in sera from mice were measured
y ELISA. ELISA plates (Nunc, Maxisorp) were coated with 100 l
c = 1 g/ml) rBet v 1, rPhl p 1, or rPhl p 5 in 0.1 M bicarbonate
uffer, pH 9.6 at 4 ◦C overnight. Plates were washed twice with TBST
ontaining 0.5% (w/v) BSA and blocked with TBST containing 3%edians are indicated by dashes. In (C) the OD values corresponding to the levels of
ime (x-axis) for the anti-Phl p 1-treated group and an anti-Bet v 1-treated control
(w/v) BSA at 37 ◦C for 3 h. After blocking, plates were incubated
with sera (duplicates) taken before and after antibody treatment
(diluted 1:1000, 1:5000, 1:10,000; 1:50,000 in TBST/0.5% (w/v)
BSA) overnight at 4 ◦C. After washing 5 times with TBST/0.5%
w/v  BSA, rabbit IgG antibodies were detected with HRP-labelled
donkey anti-rabbit IgG antibodies (GE Healthcare, Little Chalfont
Buckinghamshire, UK) diluted 1:1000 in TBST/0.5% (w/v) BSA. HRP-
labelled donkey anti-rabbit IgG antibodies showed no reactivity
with mouse sera obtained before treatment ensuring speciﬁcity for
rabbit IgG. Results represent means of duplicate determinations
with variations of less than 10%. Allergen-speciﬁc rabbit IgG levels
determined in sera 72 h, 1 week and 2 weeks after treatment were
expressed as percentages of allergen-speciﬁc IgG levels measured
24 h after treatment.
Degranulation experiments with rat basophil leukaemia cells
The rat basophil leukaemia cell subline RBL-2H3 was main-
tained in RPMI medium (Biochrom, AG, Berlin, Germany)
supplemented with 10% FCS (PAA, Pasching, Austria). RBL-2H3
cells were plated in 96-well tissue-culture plates (4–6 × 105 ml;
Nunc, Roskilde, Denmark) and incubated at 37 ◦C in 5% CO2
overnight. The cell layer was  washed twice with 1× Tyrode buffer
(137 mmol/L NaCl, 2.7 mmol/L KCl, 0.5 mmol/L MgCl2, 1.8 mmol/L
CaCl2, 0.4 mmol/L NaH2PO4, 5.6 mmol/L d-glucose, and 0.1% (w/v)
BSA, pH 7.2; Sigma–Aldrich, Vienna, Austria).
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The therapeutic effect of administered allergen-speciﬁc rabbit
gG was determined by diluting sera obtained from mice before
nd after antibody treatment 1:10 in RPMI, addition of differ-
nt doses of allergens (0.02 g/ml to 0.5 g/ml) for 10 min  to
orm immune complexes and exposing these complexes for 3 h
o RBL cells and subsequent measurement of -hexosaminidase
elease. -Hexosaminidase was measured using 80 mol/L 4-
ethyl-umbelliferyl- N-acetyl--d-glucosamine (Sigma–Aldrich)
n citrate buffer (0.1 mol/L, pH 4.5) for 1 h at 37 ◦C. The reaction
as stopped by the addition of glycine buffer (0.2 mol/L glycine,
.2 mol/L NaCl, pH 10.7), and the ﬂuorescence was  measured at an
xtinction wavelength of 360 nm to the emission wavelength of
65 nm by using a ﬂuorescence microplate reader (Perkin Elmer,
allac, Vienna, Austria). -Hexosaminidase release was  expressed
s a percentage of the total -hexosaminidase release that was
btained by lysing the cells by addition of 1% Triton-X-100 (Merck,
armstadt, Germany). Determinations were done as triplicates and
re displayed as mean values ± SDs after subtraction of background.
ackground release was determined by loading cells with sera
ithout addition of allergen.
The effects of preventive administration of allergen-speciﬁc IgG
ere studied by incubating RBL cells with sera (diluted 1:20 in
PMI medium) for 2 h. Then cells were washed two times with 1×
yrode buffer to remove unbound antibodies. Cross-linking of the
cRI-bound IgE was induced by adding different doses of allergens
0.02 g/ml to 0.5 g/ml) for 1 h. -Hexosaminidase release of RBL
ells was measured as described above.
n vivo skin testing
Intradermal skin tests were performed in mice that had been
reated prophylactically with allergen-speciﬁc antibodies before
hey were sensitized. One hundred microlitres of 0.5% Evans blue
Sigma) were injected intravenously (i.v.) into the tail veins of
he mice. Subsequently 30 l of rPhl p 5 (0.5 g/ml) and rBet v 1
0.5 g/ml) were injected intradermally into the shaved abdomi-
al skin. The mast cell degranulation compound 48/80 (20 g/ml;
igma) was used as a positive control and 1× PBS was injected as
 negative control. After 20 min  mice were sacriﬁced and skinned.
he blue staining on the inverted skin was documented by photog-
aphy.
esults
assive immunization of mice with allergen-speciﬁc IgG
ntibodies inhibits allergen-speciﬁc IgE binding
Fig. 3A–C shows the effects of passive immunization with
llergen-speciﬁc antibodies on allergen-speciﬁc IgE binding. Sera
rom mice that had received Bet v 1-speciﬁc IgG antibodies showed
 reduction of IgE binding to Bet v 1 between 23.8% and 57.4%
median: 46.5%) 24 h after antibody treatment (Fig. 3A, left panel).
ne week after antibody treatment still 27.2% inhibition of Bet v 1-
peciﬁc IgE binding was observed which decreased during the next
 weeks to 0%. No inhibition of IgE binding to Bet v 1 was  observed
n mice which had been immunized with IgG antibodies speciﬁc for
n unrelated allergen (i.e., Phl p 5) (Fig. 3A, right panel).
Similar results were obtained for Phl p 1- and Phl p 5-sensitized
ice (Fig. 3B–D). Phl p 1-sensitized mice which were treated with
hl p 1-speciﬁc IgG antibodies showed a median reduction of IgE
inding to Phl p 1 of 45.2% (ranging from 30.8 to 63.3%) 24 h after
reatment and of 20.3% after 1 week (Fig. 3B, left panel). Fig. 3C
hows the reduction of the Phl p 1-speciﬁc IgE levels for the latter
roup of mice and a control group treated with anti-Bet v 1 IgG.
o relevant inhibition of IgE binding to Phl p 1 was observed iny 218 (2013) 884– 891 887
Phl p 1-sensitized mice which had received Bet v 1-speciﬁc IgG
antibodies (Fig. 3B and C). The reduction of IgE binding to Phl p 5
in Phl p 5-sensitized mice treated with Phl p 5-speciﬁc IgG varied
between 39.7% and 76.6% (median: 66.1%) 24 h after treatment,
remained at around 69% after 1 week and even after 3 weeks was in
the range of 23.3% (Fig. 3D, left panel). No relevant inhibition of IgE
binding to Phl p 5 was found for mice which had been immunized
with Bet v 1-speciﬁc IgG (Fig. 3D, right panel).
To investigate if ﬂuctuations of total IgE levels affect the mea-
surement of allergen-speciﬁc IgE binding total IgE levels were
measured with a sandwich ELISA but were found to show no rele-
vant alterations over the treatment period (data not shown).
Kinetics of the levels of administered allergen-speciﬁc IgG
antibodies
To assess the kinetics of the levels of administered allergen-
speciﬁc IgG antibodies we compared the levels of allergen-speciﬁc
rabbit IgG in mouse sera at different time points after immuniza-
tion. The levels of allergen-speciﬁc IgG antibodies measured in the
blood of the mice 24 h after immunization were compared with the
levels measured at 72 h, 1 week and 2 weeks. 72 h after antibody
injection approximately 75% (Bet v 1), 71% (Phl p 1) or 88% (Phl p
5) of allergen-speciﬁc IgG reactivity as compared to the 24 h level
were found (Fig. 4A–C). Even after 2 weeks approximately 20% of
the administered IgG antibodies could be detected for the Bet v 1
and Phl p 1-speciﬁc IgG antibodies (i.e., Bet v 1: median 17.8%; Phl
p 1: median 24%) and almost 40% of the Phl p 5-speciﬁc IgG (i.e.,
median 39.9%). Due to the fact that the titres of allergen-speciﬁc IgG
were higher in the anti-Phl p 5 antiserum compared to the anti-Bet
v 1 and anti-Phl p 1 antisera the decline of allergen-speciﬁc rabbit
IgG was slower for the anti-Phl p 5-treated animals.
Passively applied allergen-speciﬁc IgG antibodies block immediate
allergic reactions in sensitized mice
The therapeutic potential of passively applied allergen-speciﬁc
IgG antibodies was  studied in basophil cell degranulation exper-
iments. Sera from passively immunized mice were incubated
with allergens, exposed to RBL-2H3 cells and the release of -
hexosaminidase was  measured. When sera were taken from Phl
p 5-sensitized mice shortly before administration of Phl p 5-
speciﬁc IgG antibodies a median -hexosaminidase release of 45%
was  found for a concentration of 0.02 g/ml Phl p 5 and of 78%
for 0.1 g/ml. When sera were taken from the same mice 24 h
after passive immunization a strong reduction of the RBL degra-
nulation was observed (6% median degranulation at 0.02 g/ml
Phl p 5 and 20% median degranulation at 0.1 g/ml Phl p 5)
(Fig. 5).
We  also investigated the duration of the inhibitory effect of
allergen-speciﬁc IgG in a Bet v 1-sensitized mouse. Serum sam-
ples were taken before (before) and 24 h, 72 h, 1 week, 2 weeks
and 3 weeks after treatment, incubated with Bet v 1 and then
exposed to RBL cells. Before the administration of Bet v 1-speciﬁc
IgG, Bet v 1 induced a -hexosaminidase release of approximately
35% which was fully suppressed at 24 h and remained reduced to
approximately 10% even after 3 weeks of treatment (Fig. 6).
Prophylactic application of allergen-speciﬁc IgG antibodies
prevents the development of allergen-speciﬁc IgE and IgG1
antibodies and allergic sensitizationTo evaluate whether prophylactic antibody treatment inﬂu-
ences the development of allergen-speciﬁc IgE and IgG1 responses,
mice received Phl p 5-speciﬁc rabbit IgG antibodies one day prior to
sensitization with Phl p 5 (Fig. 2). Sera from mice treated with Phl p
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Fig. 5. Inhibition of basophil degranulation by allergen-speciﬁc IgG antibodies. Two
concentrations of Phl p 5 (0.02 g/ml; 0.1 g/ml; x-axis) were pre-incubated with
sera taken before (before) and after antibody treatment (after) and exposed to RBL
cells.  The percentages of total -hexosaminidase release are displayed on the y-axis.
Medians are indicated by dashes.
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Fig. 6. Inhibition of basophil degranulation by administered allergen-speciﬁc IgG
antibodies. Bet v 1 was  pre-incubated with serum obtained before (before) or
after (24 h, 72 h, 1 week, 2 week, 3 week) treatment with Bet v 1-speciﬁc IgG. Com-
plexes were exposed to RBL cells. -Hexosaminidase release (means of triplicates)
is expressed as percentage of total -hexosaminidase release (y-axis).
Fig. 7. Development of Phl p 5-speciﬁc IgE antibodies in mice after prophylactic
administration of Phl p 5-speciﬁc IgG antibodies (left panel) or Phl p 2-speciﬁc IgGera taken 24 h after treatment and displayed on the y-axes. Medians are indicated
y  dashes.
-speciﬁc IgG antibodies showed no relevant IgE and IgG1 binding
o Phl p 5 (Fig. 7, left panel and Fig. 8, left panel) whereas sera of
ice which had received antibodies with speciﬁcity to an unrelated
llergen, Phl p 2 displayed robust IgE and IgG1 binding to rPhl p 5
Fig. 7, right panel and Fig. 8, right panel). The development of Bet 1-speciﬁc IgE and IgG1 antibodies was neither affected in mice
eceiving Phl p 5-speciﬁc nor in mice receiving Phl p 2-speciﬁc IgG
ntibodies (data not shown).
antibodies (right panel) at different points of time (x-axes; −1day, 8day, 20day). OD
levels (means of duplicates) (y-axes) correspond to bound IgE antibodies. Medians
are indicated by dashes.
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In order to study whether the lack of allergen-speciﬁc IgE bind-
ng is due to the presence of the administered allergen-speciﬁc IgG
ntibodies which compete with IgE for the binding to the allergen
r due to the suppression of the development of allergic sensi-
ization we performed basophil degranulation experiments. RBL
ells bound only mouse IgE but not the administered competing
llergen-speciﬁc rabbit IgG (data not shown). Fig. 9A, left panel
hows that RBL cells exposed to sera from mice which had received
rophylactic immunization with Phl p 5-speciﬁc IgG induced no rel-
vant Phl p 5-speciﬁc degranulation even 20 days after treatment.
his effect was found to last even for 40 days despite a second sensi-
ization given at day 22 after the ﬁrst sensitization (data not shown).
y contrast, mice which had received a prophylactic immunization
ith unrelated (i.e., Phl p 2-speciﬁc) IgG showed Phl p 5-speciﬁc
asophil degranulation (Fig. 9A, right panel).
The in vivo relevance of the prophylactic immunization was
hown by in vivo skin testing. No Phl p 5-speciﬁc skin reaction could
e induced in mice which had received Phl p 5-speciﬁc IgG antibod-
es before sensitization whereas reactions to Bet v 1 and compound
8/80 were not affected (Fig. 9B, left panel). By contrast, Phl p 5-
peciﬁc skin reactions were elicited in mice which had been treated
ith Phl p 2-speciﬁc IgG antibodies (Fig. 9B, right panel).
iscussion
In this study we demonstrated in mouse models of allergic
ensitization to clinically relevant pollen allergens that passive
mmunization with allergen-speciﬁc IgG antibodies is effective for
reatment and prevention of allergy. In a model for treatment we
sed three important seasonal pollen allergens, Bet v 1, the major
irch pollen allergen, as well as Phl p 1 and Phl p 5, two  major grass
ollen allergens (Niederberger et al. 1998a; Niederberger et al.
998b; Westritschnig et al. 2008) for sensitization and highly spe-
iﬁc rabbit IgG antibodies which were obtained by immunization
ith the puriﬁed recombinant allergens for treatment.
In order to mimic  the treatment of established allergy, mice
ere sensitized ﬁrst and then received passive immunization
ith allergen-speciﬁc IgG antibodies. Single passive administra-
ion inhibited allergen-speciﬁc IgE binding and allergen-induced
asophil degranulation for a period of up to 3 weeks.
Similar observations were made earlier in mouse models
ased on the model antigen ovalbumin where it was  shown
hat intranasally (i.n.) administered OVA-speciﬁc IgG antibodiesy 218 (2013) 884– 891 889
reduced signs of allergic asthma (Moerch et al. 2006; Sehra et al.
2003). The authors proposed OVA interception through IgG and
FcR binding on alveolar macrophages followed by an increase of
INF--secreting T cells as responsible mechanism for this inhibi-
tion (Sehra et al. 2003). By contrast, Strait et al. suggested that
the protective effect of allergen-speciﬁc IgG may  be mediated by
two  mechanisms, one being capture of antigen before it can cross-
link FcRI-bound IgE and the other being cross-linking of FcRI
to the inhibitory FcRIIb through the allergen/IgG/IgE complex
(Strait et al. 2006). In our models the allergen-speciﬁc IgG was
in excess to IgE because after administration of IgG almost no IgE
binding to allergens could be detected. It is therefore most likely
that the inhibition of basophil degranulation and the inhibition of
IgE sensitization observed in our models were due to capture of
allergen. We  think that passive immunization could be a possi-
ble treatment option especially for seasonal allergies (e.g., pollen
allergies) which may  be treated by one pre-seasonal and eventu-
ally an additional maintenance immunization depending on the
length of the pollen season. In fact, it has been demonstrated that
human allergen-speciﬁc IgG antibodies can be identiﬁed for such
a purpose (Visco et al. 1996; Flicker et al. 2002; Padavattan et al.
2009). These antibodies can be modiﬁed to increase afﬁnity, in vivo
half-life and mechanisms of action through modiﬁcation of their
constant domains (e.g., mutation of CDRs, change of glycosyla-
tion, ability to bind to Fc-receptors) (reviewed in Flicker et al.
2011).
In a second set of our experiments we investigated whether
prophylactic administration of allergen-speciﬁc IgG antibodies in
naïve mice can prevent allergic sensitization. Interestingly, we
found that mice having received allergen-speciﬁc IgG antibodies
neither developed allergen-speciﬁc IgE nor allergen-speciﬁc IgG
responses and failed to exhibit any allergic reactions. This sup-
pression was  allergen-speciﬁc because the IgE and IgG responses
against another unrelated allergen were not inhibited. We  con-
sider the latter ﬁnding interesting because it is in agreement with
data showing that allergen-speciﬁc IgG antibodies which are trans-
mitted from SIT-treated mothers to their children may protect
against allergic sensitization (Glovsky et al. 1991). It has also been
reported that children with high allergen-speciﬁc IgG levels in cord
blood develop less frequently allergies (Jenmalm and Bjorksten
2000). Furthermore, data from experimental animal models sug-
gest that pre-conceptional immunization with allergens or passive
immunization with allergen-speciﬁc IgG leads to transmission of
allergen-speciﬁc IgG to the off-spring and prevents allergic sen-
sitization (Fusaro et al. 2007; Polte and Hansen 2008; Polte et al.
2008; Uthoff et al. 2003; Victor et al. 2010). Based on these and
the ﬁndings in our study one may  envision pre-conceptional, early
post-conceptional passive immunization or other forms of admin-
istration of allergen-speciﬁc IgG (e.g., oral) as possible strategies for
the prevention of allergy.
Experimental animal models of allergy are useful to study cer-
tain aspects of allergy (Helm and Burks 2004) but unfortunately
do not completely resemble allergy in humans. For example, it is
well established that mice recognize different epitopes on allergens
compared to allergic patients. Furthermore, respiratory allergy in
mice does not resemble human disease because generally high
doses of allergens need to be administered to obtain airway inﬂam-
mation which then involves mechanisms of inﬂammation distinct
from those operative in humans (i.e., mainly T cell-mediated
inﬂammation) (Epstein 2004). Yet our results demonstrate that
passive immunization with allergen-speciﬁc IgG antibodies had a
profound inhibitory effect on IgE-mediated effector cell degranu-
lation, which is a major mechanism of allergy in allergic patients
and on the induction of allergic sensitization. Since IgE epitopes
on allergens recognized by mice and man  are different (Epstein
2004) it will be necessary to isolate human allergen-speciﬁc IgG
890 S. Flicker et al. / Immunobiology 218 (2013) 884– 891
Fig. 9. (A) Effects of the application of allergen-speciﬁc IgG antibodies on basophil degranulation. Sera from mice obtained before (−1day) or after administration of Phl p
5-speciﬁc IgG (left panel) or Phl p 2-speciﬁc IgG (right panel) (24 h, 8day, 20day) were exposed to RBL cells. Then cells were washed and exposed to Phl p 5. -Hexosaminidase
releases (dashes indicate medians) are expressed as percentage of total releases (y-axes). (B) Lack of Phl p 5-speciﬁc immediate skin reactions in mice treated with Phl p
5 l p 5-s
i
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p-speciﬁc IgG. Evans blue extravasation in a representative mouse treated with Ph
ntra-dermal injection of Phl p 5, Bet v 1, 48/80 or PBS.
ntibodies which block the binding of allergic patients IgE and to
erform ﬁrst clinical studies directly in allergic patients after care-
ul evaluation of eventual harmful effects of therapeutic antibodies
n toxicology studies rather then in laborious but incomplete allergy
odels in animals. In fact it has been shown that human antibodies
ith a suitable blocking activity even for polyclonal IgE responses
an be identiﬁed (Flicker et al. 2002; Visco et al. 1996). Once these
ntibodies can be produced in recombinant form and suitable qual-
ty for safe clinical trials, it should be possible to evaluate whether
assive immunization with allergen-speciﬁc IgG antibodies may  be
n effective strategy for the treatment of allergy as well as for the
revention of allergic sensitization.peciﬁc (left panel) or in mouse treated with Phl p 2-speciﬁc IgG (right panel) after
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